@Article{Naseripour2016,
journal="Journal of Contemporary Brachytherapy",
issn="1689-832X",
volume="8",
number="1",
year="2016",
title="Ruthenium-106 brachytherapy for thick uveal melanoma: reappraisal of apex and base dose radiation and dose rate",
abstract=" Purpose:  To evaluate the outcomes of ruthenium-106 ( 106 Ru) brachytherapy in terms of radiation parameters in patients with thick uveal melanomas.   Material and methods:   Medical records of 51 patients with thick (thickness ≥ 7 mm and < 11 mm) uveal melanoma treated with  106 Ru brachytherapy during a ten-year period were reviewed. Radiation parameters, tumor regression, best corrected visual acuity (BCVA), and treatment-related complications were assessed.   Results:   Fifty one eyes of 51 consecutive patients including 25 men and 26 women with a mean age of 50.5 ± 15.2 years were enrolled. Patients were followed for 36.1 ± 26.5 months (mean ± SD). Mean radiation dose to tumor apex and to sclera were 71 (± 19.2) Gy and 1269 (± 168.2) Gy. Radiation dose rates to tumor apex and to sclera were 0.37 (± 0.14) Gy/h and 6.44 (± 1.50) Gy/h. Globe preservation was achieved in 82.4%. Preoperative mean tumor thickness of 8.1 (± 0.9) mm decreased to 4.5 (± 1.6) mm, 3.4 (± 1.4) mm, and 3.0 (± 1.46) mm at 12, 24, and 48 months after brachytherapy (p = 0.03). Four eyes that did not show regression after 6 months of brachytherapy were enucleated. Secondary enucleation was performed in 5 eyes because of tumor recurrence or neovascular glaucoma. Tumor recurrence was evident in 6 (11.8%) patients. Mean Log MAR (magnification requirement) visual acuity declined from 0.75 (± 0.63) to 0.94 (± 0.5) (p = 0.04). Best corrected visual acuity of 20/200 or worse was recorded in 37% of the patients at the time of diagnosis and 61.7% of the patients at last exam (p = 0.04). Non-proliferative and proliferative radiation-induced retinopathy was observed in 20 and 7 eyes.   Conclusions : Thick uveal melanomas are amenable to  106 Ru brachytherapy with less than recommended apex radiation dose and dose rates.",
author="Naseripour, Masood
and Jaberi, Ramin
and Sedaghat, Ahad
and Azma, Zohreh
and Nojomi, Marzieh
and Falavarjani, Khalil Ghasemi
and Nazari, Hossein",
pages="66--73",
doi="10.5114/jcb.2016.57818",
url="http://dx.doi.org/10.5114/jcb.2016.57818"
}